Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,624,800.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00. Following the completion of the sale, the director now directly owns 2,041,931 shares of the company’s stock, valued at $221,181,965.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Trading Up 1.7 %

NASDAQ:MRNA opened at $107.97 on Friday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The stock has a market capitalization of $41.34 billion, a PE ratio of -8.70 and a beta of 1.62. The business’s 50-day simple moving average is $102.54 and its 200-day simple moving average is $93.77.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the previous year, the business posted $3.61 EPS. Moderna’s revenue for the quarter was down 44.9% on a year-over-year basis. Sell-side analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MRNA. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research report on Tuesday, January 2nd. Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $126.49.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently modified their holdings of MRNA. Vanguard Group Inc. lifted its stake in Moderna by 22.6% in the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after acquiring an additional 6,248,623 shares in the last quarter. Wellington Management Group LLP lifted its stake in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after acquiring an additional 1,690,341 shares in the last quarter. Norges Bank bought a new stake in Moderna in the 4th quarter valued at approximately $347,565,000. Finally, Invesco Ltd. lifted its stake in Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after acquiring an additional 517,683 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.